TickerStat.comEloxx Pharmaceuticals annual return on assets (roa)
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Return on Assets (ROA) Growth & History (ELOX)
Eloxx Pharmaceuticals's return on assets (roa) was −145.40% for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −145.40% | −11.32 pp |
| 2024 | 2024-12-31 | −134.09% | +15.28 pp |
| 2023 | 2023-12-31 | −149.37% | −40.51 pp |
| 2022 | 2022-12-31 | −108.86% | +77.49 pp |
| 2021 | 2021-12-31 | −186.35% | −105.39 pp |
| 2020 | 2020-12-31 | −80.95% | +11.83 pp |
| 2019 | 2019-12-31 | −92.78% | +32.21 pp |
| 2018 | 2018-12-31 | −124.99% | +13.53 pp |
| 2017 · Dec 31 | 2017-12-31 | −138.52% | +20.89 pp |
| 2017 · Jun 30 | 2017-06-30 | −129.19% | −62.70 pp |
| 2016 · Dec 31 | 2016-12-31 | −159.41% | −123.01 pp |
| 2016 · Jun 30 | 2016-06-30 | −66.49% | +1.83 pp |
| 2015 · Dec 31 | 2015-12-31 | −36.41% | — |
| 2015 · Jun 30 | 2015-06-30 | −68.32% | −22.68 pp |
| 2014 | 2014-06-30 | −45.63% | +41.50 pp |
| 2013 | 2013-06-30 | −87.14% | −21.99 pp |
| 2012 | 2012-06-30 | −65.15% | — |
Eloxx Pharmaceuticals quarterly return on assets (roa)
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q4 2023 | 2023-12-31 | −149.37% | −40.51 pp |
| Q3 2023 | 2023-09-30 | −124.43% | −22.72 pp |
| Q2 2023 | 2023-06-30 | −125.33% | −30.81 pp |
| Q1 2023 | 2023-03-31 | −120.72% | +97.00 pp |
| Q4 2022 | 2022-12-31 | −108.86% | +77.49 pp |
| Q3 2022 | 2022-09-30 | −101.71% | +35.88 pp |
| Q2 2022 | 2022-06-30 | −94.52% | +19.86 pp |
| Q1 2022 | 2022-03-31 | −217.72% | −130.71 pp |
| Q4 2021 | 2021-12-31 | −186.35% | −105.39 pp |
| Q3 2021 | 2021-09-30 | −137.59% | −58.22 pp |
| Q2 2021 | 2021-06-30 | −114.38% | −36.47 pp |
| Q1 2021 | 2021-03-31 | −87.01% | +14.79 pp |
| Q4 2020 | 2020-12-31 | −80.95% | +11.83 pp |
| Q3 2020 | 2020-09-30 | −79.37% | +6.13 pp |
| Q2 2020 | 2020-06-30 | −77.91% | −5.96 pp |
| Q1 2020 | 2020-03-31 | −101.80% | +31.04 pp |
| Q4 2019 | 2019-12-31 | −92.78% | +32.21 pp |
| Q3 2019 | 2019-09-30 | −85.51% | +53.13 pp |
| Q2 2019 | 2019-06-30 | −71.95% | +32.56 pp |
| Q1 2019 | 2019-03-31 | −132.84% | +84.05 pp |
| Q4 2018 | 2018-12-31 | −124.99% | +26.89 pp |
| Q3 2018 | 2018-09-30 | −138.64% | +28.76 pp |
| Q2 2018 | 2018-06-30 | −104.50% | +5.37 pp |
| Q1 2018 · Mar 31 | 2018-03-31 | −216.90% | −149.17 pp |
| Q4 2017 · Dec 31 | 2017-12-31 | −151.88% | −88.43 pp |
| Q1 2018 · Sep 30 | 2017-09-30 | −167.39% | −99.19 pp |
| Q4 2017 · Jun 30 | 2017-06-30 | −109.87% | −52.40 pp |
| Q1 2017 · Mar 31 | 2017-03-31 | −67.72% | −9.34 pp |
| Q4 2016 · Dec 31 | 2016-12-31 | −63.45% | −27.36 pp |
| Q1 2017 · Sep 30 | 2016-09-30 | −68.20% | −13.30 pp |
| Q4 2016 · Jun 30 | 2016-06-30 | −57.47% | +10.85 pp |
| Q1 2016 · Mar 31 | 2016-03-31 | −58.39% | +91.05 pp |
| Q4 2015 · Dec 31 | 2015-12-31 | −36.08% | +110.61 pp |
| Q1 2016 · Sep 30 | 2015-09-30 | −54.90% | +19.46 pp |
| Q4 2015 · Jun 30 | 2015-06-30 | −68.32% | −22.68 pp |
| Q3 2015 | 2015-03-31 | −149.44% | −65.62 pp |
| Q2 2015 | 2014-12-31 | −146.70% | −72.19 pp |
| Q1 2015 | 2014-09-30 | −74.37% | +22.05 pp |
| Q4 2014 | 2014-06-30 | −45.63% | +41.50 pp |
| Q3 2014 | 2014-03-31 | −83.82% | −11.29 pp |
| Q2 2014 | 2013-12-31 | −74.51% | +20.53 pp |
| Q1 2014 | 2013-09-30 | −96.42% | −12.29 pp |
| Q4 2013 | 2013-06-30 | −87.14% | −21.99 pp |
| Q3 2013 | 2013-03-31 | −72.53% | — |
| Q2 2013 | 2012-12-31 | −95.04% | — |
| Q1 2013 | 2012-09-30 | −84.13% | — |
| Q4 2012 | 2012-06-30 | −65.15% | — |
Eloxx Pharmaceuticals return on assets (roa) trends
Over the last five fiscal years, Eloxx Pharmaceuticals's return on assets (roa) decreased from −80.95% to −145.40%, a change of −64.45 percentage points. The latest reported quarter, Q4 2023, shows −149.37%.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...